Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/DNTH · Entity 1813 | Director | May 21, 2026 | May 22, 2026 |
| Keenova Therapeutics plcMNKPF · Entity 28960 | EVP & Chief Sci. Ofcr | June 16, 2022 | June 21, 2022 |
| Silence Therapeutics plcSLN · Entity 5028 | EVP and Chief R&D Officer | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date May 21, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $89.63 · Expires 2036-05-21 | Direct | 6,090 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 6,090 · Balance 6,090 F1: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 1
1 source rowRow 1 · 2022-06-16 · Disposition to issuer · Disposed 72,637 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.27 · Expires 2025-07-01 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-16 · Disposition to issuer · Disposed 11,275 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.61 · Expires 2026-01-04 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-06-16 · Disposition to issuer · Disposed 22,288 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.73 · Expires 2027-01-03 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-06-16 · Disposition to issuer · Disposed 59,731 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.73 · Expires 2027-01-03 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-06-16 · Disposition to issuer · Disposed 59,731 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.80 · Expires 2028-04-02 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-06-16 · Disposition to issuer · Disposed 189,201 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
| Employee Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.26 · Expires 2029-04-01 | Direct | 0 |
Reported balance
After 2022-06-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-06-16 · Disposition to issuer · Disposed 102,801 · Balance 0 F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code.
F2: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy.
F3: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan.
Silence Therapeutics plc
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.05 · Expires 2036-01-02 | Direct | 300,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 300,000 · Balance 300,000 F1: One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 22, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 6,090 | $0.00 Strike: $89.63 | $0.00 |
DisclosureSEC source: 0001639860-26-000005 · ownership.xml · derivative · entry 1 Romano Steven J. · CIK 0001639860 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,090 Underlying: Common Stock · 6,090 shares Expires 2036-05-21 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:15 UTC | Silence Therapeutics plc SLN · Entity 5028 | GrantEmployee Share Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001639860-26-000002 · form4-01062026_040105.xml · derivative · entry 1 Romano Steven J. · CIK 0001639860 · EVP and Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Ordinary Shares · 300,000 shares Expires 2036-01-02 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date. Read SEC document |
| May 22, 2025 Filed May 22, 2025 20:42 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.36 | $0.00 |
DisclosureSEC source: 0000950170-25-076408 · ownership.xml · derivative · entry 1 Romano Steven J. · CIK 0001639860 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:15 UTC | Silence Therapeutics plc SLN · Entity 5028 | GrantEmployee Share Option (Right to Buy) · Derivative | 285,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-25-000745 · form4-01062025_040106.xml · derivative · entry 1 Romano Steven J. · CIK 0001639860 · EVP and Chief R&D Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,000 Underlying: Ordinary Shares · 285,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option shall vest on January 2, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such vesting date. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:38 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $26.42 | $0.00 |
DisclosureSEC source: 0000950170-24-107900 · ownership.xml · derivative · entry 1 Romano Steven J. · CIK 0001639860 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2034-09-15 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:10 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 102,801 | $0.00 Strike: $22.26 | $0.00 |
DisclosureSEC source: 0000899243-22-023426 · doc4.xml · derivative · entry 7 Romano Steven J. · CIK 0001639860 · EVP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 102,801 shares Expires 2029-04-01 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:10 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 189,201 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0000899243-22-023426 · doc4.xml · derivative · entry 6 Romano Steven J. · CIK 0001639860 · EVP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 189,201 shares Expires 2028-04-02 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:10 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 59,731 | $0.00 Strike: $51.73 | $0.00 |
DisclosureSEC source: 0000899243-22-023426 · doc4.xml · derivative · entry 5 Romano Steven J. · CIK 0001639860 · EVP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 59,731 shares Expires 2027-01-03 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:10 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 59,731 | $0.00 Strike: $51.73 | $0.00 |
DisclosureSEC source: 0000899243-22-023426 · doc4.xml · derivative · entry 4 Romano Steven J. · CIK 0001639860 · EVP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 59,731 shares Expires 2027-01-03 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:10 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 22,288 | $0.00 Strike: $72.61 | $0.00 |
DisclosureSEC source: 0000899243-22-023426 · doc4.xml · derivative · entry 3 Romano Steven J. · CIK 0001639860 · EVP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,288 shares Expires 2026-01-04 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:10 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerEmployee Share Options (Right to Buy) · Derivative | 11,275 | $0.00 Strike: $120.27 | $0.00 |
DisclosureSEC source: 0000899243-22-023426 · doc4.xml · derivative · entry 2 Romano Steven J. · CIK 0001639860 · EVP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,275 shares Expires 2025-07-01 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:10 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerOrdinary Shares | 72,637 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023426 · doc4.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · EVP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On October 12, 2020, Mallinckrodt plc, an Irish public limited company in examination under Part 10 of the Companies Act 2014 of Ireland ("Mallinckrodt"), and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On February 3, 2022, the Bankruptcy Court issued an opinion (which was subsequently revised on February 8, 2022 to make minor corrections) stating its intention to confirm Mallinckrodt's Fourth Amended Joint Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code. F2 · kind: (Continued from Footnote 1) On March 2, 2022, the Bankruptcy Court entered an order confirming the Fourth Amended Joint Plan of Reorganization (with Technical Modifications) of Mallinckrodt Plc and Its Debtor Affiliates Under Chapter 11 of the Bankruptcy Code (as amended, supplemented or otherwise modified, the "Plan"), and on June 16, 2022 (the "Effective Date"), the Plan became effective and Mallinckrodt emerged from bankruptcy. F3 · kind: On the Effective Date, all of Mallinckrodt's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such ordinary shares, were cancelled and extinguished pursuant to the Plan. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:45 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 3,022 | $1.80 | $5,439.60 |
DisclosureSEC source: 0000950138-20-000204 · edgar.xml · nonDerivative · entry 2 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,637 Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:45 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,924 | $1.93 | $3,713.32 |
DisclosureSEC source: 0000950138-20-000204 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,659 Read SEC document |
| January 04, 2020 Filed Jan 8, 2020 00:57 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 284 | $3.26 | $925.84 |
DisclosureSEC source: 0000950138-20-000017 · edgar.xml · nonDerivative · entry 2 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,583 F1 · balance_after: Includes 505 shares acquired under the Mallinckrodt employee stock purchase plan. Read SEC document |
| January 03, 2020 Filed Jan 8, 2020 00:57 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 883 | $3.36 | $2,966.88 |
DisclosureSEC source: 0000950138-20-000017 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,867 F1 · balance_after: Includes 505 shares acquired under the Mallinckrodt employee stock purchase plan. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 11:54 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 285 | $9.09 | $2,590.65 |
DisclosureSEC source: 0000950138-19-000370 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,245 F1 · balance_after: Includes 1,204 shares acquired under the Mallinckrodt employee stock purchase plan. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 21:46 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 3,103 | $22.80 | $70,748.40 |
DisclosureSEC source: 0000950138-19-000221 · edgar.xml · nonDerivative · entry 2 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,326 Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:46 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 102,801 | $0.00 Strike: $22.26 | $0.00 |
DisclosureSEC source: 0000950138-19-000221 · edgar.xml · derivative · entry 3 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,801 Underlying: Ordinary Shares · 102,801 shares Expires 2029-04-01 F2 · derivative.exercise_date: The options vest in four equal annual installments beginning April 1, 2020. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:46 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 22,462 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000221 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,429 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning April 1, 2020. Read SEC document |
| January 04, 2019 Filed Jan 7, 2019 23:02 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 431 | $17.21 | $7,417.51 |
DisclosureSEC source: 0000950138-19-000023 · edgar.xml · nonDerivative · entry 2 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,967 Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 23:02 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 980 | $16.14 | $15,817.20 |
DisclosureSEC source: 0000950138-19-000023 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,398 Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 20:29 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 285 | $18.66 | $5,318.10 |
DisclosureSEC source: 0000950138-18-000463 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,378 Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 22:11 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 189,201 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0000950138-18-000313 · edgar.xml · derivative · entry 2 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,201 Underlying: Ordinary Shares · 189,201 shares Expires 2028-04-02 F3 · derivative.exercise_date: The options vest in four equal annual installments beginning April 2, 2019. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 22:11 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 36,232 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000313 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,663 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning April 2, 2019. F2 · balance_after: Includes 842 shares acquired on March 31, 2018 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| January 04, 2018 Filed Jan 6, 2018 00:33 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 507 | $23.40 | $11,863.80 |
DisclosureSEC source: 0000950138-18-000047 · edgar.xml · nonDerivative · entry 2 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,589 Read SEC document |
| January 03, 2018 Filed Jan 6, 2018 00:33 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 1,136 | $23.51 | $26,707.36 |
DisclosureSEC source: 0000950138-18-000047 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,096 Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 22:37 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 2,000 | $21.96 | $43,920.00 |
DisclosureSEC source: 0000950138-17-000758 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,232 F1 · balance_after: Includes 246 shares acquired between April 1, 2017 and September 30, 2017 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 20:17 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 310 | $44.81 | $13,891.10 |
DisclosureSEC source: 0000950138-17-000516 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,986 Read SEC document |
| June 09, 2017 Filed Jun 12, 2017 20:16 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 1,000 | $39.88 | $39,881.00 |
DisclosureSEC source: 0000950138-17-000476 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,296 F1 · price: The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $39.88 to $39.89, inclusive. Mr. Romano will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. F2 · balance_after: Includes 273 shares acquired on March 31, 2017 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| February 10, 2017 Filed Feb 13, 2017 13:46 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 1,000 | $49.68 | $49,680.00 |
DisclosureSEC source: 0000950138-17-000152 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,023 F1 · balance_after: Includes 180 shares acquired on December 31, 2016 under the Mallinckrodt employee stock purchase plan. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 02:18 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 59,731 | $0.00 Strike: $51.73 | $0.00 |
DisclosureSEC source: 0000950138-17-000025 · edgar.xml · derivative · entry 3 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,731 Underlying: Ordinary Shares · 59,731 shares Expires 2027-01-03 F4 · derivative.exercise_date: The options vest in their entirety on January 3, 2021. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 02:18 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantEmployee Share Options (Right to Buy) · Derivative | 59,731 | $0.00 Strike: $51.73 | $0.00 |
DisclosureSEC source: 0000950138-17-000025 · edgar.xml · derivative · entry 2 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,731 Underlying: Ordinary Shares · 59,731 shares Expires 2027-01-03 F3 · derivative.exercise_date: The options vest in four equal annual installments beginning January 3, 2018. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 02:18 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 10,633 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000025 · edgar.xml · nonDerivative · entry 1 Romano Steven J. · CIK 0001639860 · Exec. VP & Chief Sci. Ofcr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,843 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning January 3, 2018. F2 · balance_after: Includes 197 shares acquired on September 30, 2016 under the Mallinckrodt employee stock purchase plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.